Figure S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Endocrine therapy improved viability in PDOs more effectively for specific subtypes of breast cancer.
• Precision treatment approaches demonstrate significant benefits over traditional methods for HR+/HER2− cases.
• Observational analysis of PDOs grouped by subtype reveals patterns in treatment efficacy.
• Findings support tailored therapies, suggesting advancements in individualizing treatment for breast cancer patients.